◆英語タイトル:Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight
◆発行会社(調査会社):KuicK Research
Single userUSD2,400 ⇒換算¥247,200見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥494,400見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。


Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70 percent of the world’s cancer deaths also occur in these regions. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.
Owing to this, the cancer segment of pharmaceutical industry is most studied and highly competitive in nature. The chemotherapeutic products are extremely diverse ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies including the miscellaneous drugs. All the aforementioned drugs are formulated in a way to be step ahead in targeted approach from their predecessor. Nevertheless, all the above mentioned therapies have their own limitations; either they should be given in conjunction with other therapies, require high dose or have got enormous side effects and so on. They too have different pharmacological parameters, overlapping boundaries and cost effectiveness.

One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. The market for angiogenesis inhibitors is quiet optimistic as they have emerged as the new targeted therapy for the cancer treatment. These molecules due their specificity are gaining a lot of manufacturer’s interest. With advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Angiogenesis is an important hallmark of tumor development. Hence, targeting angiogenesis is for sure help to eradicate the cancer. Similarly, metastasis is now a validated target for cancer treatment, the overall benefits of anti-angiogenic drugs from the perspective of impacting survival have left much to desire, endorsing a need for developing more effective therapeutic regimens. The anti angiogenic drugs are being combined with established conventional chemotherapeutic drugs to produce the desirable effect. There are now several agents available in the market such as bevacizumab that target the tumor vasculature through different pathways, either by inhibiting formation of the tumor neovasculature or by directly targeting the mature tumor vessels.

Although it has been found that their effects are compounded by their synergistic use with conventional chemotherapy rather than individual agents. For instance, an antiangiogenic drug such as bevacizumab is potent enough to bring about a transient functional normalization of the tumor vasculature. So, in order to get the maximum results out of it; this can be co-administered with chemo/radiotherapy.

Therapeutic innovations in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

In future, the information drawn from genome medical science and genome-informatics that clearly identifies the disease centric antigens valuable for medical treatment is being employed to develop the therapy using mAbs. Currently, the more attention is getting paid toward targeted therapy. Several angiogenesis inhibitors, alone and in combination with other conventional therapies, are being tested in phase I and phase II clinical trials at the moment. The health market in coming years is sure to get loaded with BsAbs with prior approval of these prospective drugs.

Hence, it is quiet predictable that global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate during the forecast period. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:
• Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
• Modulators & Mechanism of Angiogenesis
• Classification of Angiogenesis Inhibitors
• Metronomic Therapy – A Recent Advancement in Anti-Angiogenesis Therapy
• Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
• Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
• Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs


1. Angiogenesis: History and Quest for Treatment

2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention
2.1 Hallmarks of Cancer
2.1.1 Self Sufficiency in Growth Signals
2.1.2 Insensitivity to Antigrowth Signals
2.1.3 Acquired Capability: Evading Apoptosis
2.1.4 Limitless Replicative Potential
2.1.5 Sustained Angiogenesis
2.1.6 Tissue Invasion & Metastasis
2.2 Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies

3. What is Angiogenesis?
3.1 Stages of Angiogenesis
3.2 Types of Angiogenesis
3.2.1 Sprouting Angiogenesis
3.2.2 Intussusceptive Angiogenesis or Splitting Angiogenesis

4. Modulators of Angiogenesis
4.1 VEGF & Angiogenesis
4.2 Platelet Derived Growth Factor
4.3 Fibroblast Growth Factors (FGFs) & FGF Receptors
4.4 Endothelins & Endothelin Receptors
4.5 Erythropoietin & Erythropoietin Receptor
4.6 Angiopoietins & Tie2 Receptor

5. Mechanism of Angiogenesis
5.1 Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels
5.2 Endothelial Cells Proliferation & Migration
5.3 Assembling of Endothelial Cells, Formation of Cords & Lumen
5.4 Long-Term Survival of Vascular Endothelium
5.5 Differentiation of Vascular Endothelium to Meet Local Needs

6. Classification of Angiogenesis Inhibitors
6.1 Direct Endogenous Inhibitors of Angiogenesis
6.2 Indirect Inhibitors of Angiogenesis
6.3 Conventional Chemotherapeutic Agents
6.4 VEGF Targeted Therapy
6.5 FGF Targeted Therapies
6.6 Oncogene Targeted Therapy
6.7 Matrix Degrading & Remodeling Targeted Therapy
6.8 Stromal Tumor Associated Cell Targeted Therapy
6.9 Cell Adhesion Molecules (CAMs) Targeted Therapy
6.10 Inflammatory Angiogenesis Targeted Therapy

7. Metronomic Therapy – A Recent Advancement in Anti-Angiogenesis Therapy

8. Applications of Angiogenesis Inhibitors
8.1 Quantitation & Prognosis of Malignant Disorders
8.2 Antiangiogenic Therapies
8.2.1 Cancer
8.2.2 Interferon Alpha-2α to Treat Hemangiomas
8.2.3 Ocular Neovascularization

9. Global Angiogenesis Inhibitors Market overview
9.1 Current Market Scenario
9.2 Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview

10. Global Cancer Angiogenesis Inhibitors Market Dynamics
10.1 Favorable Market Parameters
10.1.1 Large Global Patient Pool
10.1.2 Severity of the Disease
10.1.3 Side Effects of the Existing Drugs
10.1.4 Unmet Requirement of Completely Curative Agents
10.2 Major Challenges of Cancer Angiogenesis Inhibitors Market
10.2.1 Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs
10.2.2 Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy
10.2.3 Need of the Better Therapy Models
10.2.4 Approval from Regulatory Guidelines: A Major Challenge
10.2.5 Journey of Drug from Bench to Bedside: A Matter of Money & Time

11. Concluding Remarks & Future Market Prospects

12. Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration

13. Marketed Cancer Angiogenesis Inhibitors Clinical Insight by Company & Indication
13.1 Apatinib
13.2 Lenalidomide (Ladevina & Revlimid)
13.3 Pomalidomide (Imnovid & Pomalyst)
13.4 Sorafenib (Nexavar)
13.5 Thalidomide (Thaled, Thalidomide Celgene & Thalomid)
13.6 Pazopanib (Votrient)
13.7 Bevacizumab (Avastin)
13.8 Bevacizumab Biosimilar (Cizumab)
13.9 Cetuximab (Erbitux)
13.10 Axitinib (Inlyta)
13.11 Recombinant Human Endostatin (Endostar & Endu)

14. Discontinued & Suspended Cancer Angiogenesis Inhibitors Clinical Pipeline by Company & Phase
14.1 No Development Reported
14.2 Discontinued
14.3 Suspended

15. Competitve Landscape
15.1 Advenchen Laboratories
15.2 Allergan
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Angstrom Pharmaceuticals
15.6 Acceleron Pharma
15.7 Biocon
15.8 Bionomics
15.9 CASI Pharmaceuticals
15.10 Celgene Corporation
15.11 Enzon Pharmaceuticals
15.12 Five Prime Therapeutics
15.13 Fujifilm Kyowa Kirin Biologics
15.14 Genentech
15.15 Genexine
15.16 Hetero Drugs
15.17 ImClone Systems
15.18 Intas Pharmaceuticals
15.19 Kyowa Hakko Kirin
15.20 Levolta Pharmaceuticals
15.21 Mabtech
15.22 Marsala Biotech
15.23 Neumedicines
15.24 Novartis
15.25 Oncobiologics
15.26 Onyx Pharmaceuticals
15.27 Pfizer
15.28 Philogen
15.29 TBG Diagnostics
15.30 Reliance Life Sciences
15.31 Roche
15.32 Samsung Bioepis
15.33 Simcere Pharmaceutical Group
15.34 SynCore Biotechnology
15.35 TaiRx
15.36 Taiwan Liposome Company
15.37 Tiltan Pharma
15.38 XBiotech

Figure 3-1: Different Stages of Involved in Angiogenesis
Figure 3-2: Different Types of Angiogenesis
Figure 3-3: Steps Involved in Sprouting Angiogenesis
Figure 3-4: Steps Involved in Splitting Angiogenesis
Figure 4-1: Different Types of Modulators of Angiogenesis
Figure 4-2: Pathway Followed by VEGF during Angiogenesis
Figure 4-3: Modulatory Pathway of FGF in Angiogenesis
Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis
Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells
Figure 6-1: Various Categories of Angiogenesis Inhibitors
Figure 8-1: Important Applications of Angiogenic Inhibitors
Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016
Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016
Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016
Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016
Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market
Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market
Figure 15-1: Advenchen Laboratories - Clinical Pipeline
Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline
Figure 15-3: Alnylam Pharmaceuticals – Clinical Pipeline
Figure 15-4: Amgen - Clinical Pipeline
Figure 15-5: Acceleron Pharma – Clinical Pipeline
Figure 15-6: Biocon - Clinical Pipeline
Figure 15-7: Bionomics – Clinical Pipeline
Figure 15-8: Casi Pharmaceutical - Clinical Development
Figure 15-9: Celgene - Clinical Pipeline
Figure 15-10: Five Prime Therapeutics – Clinical Pipeline
Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline
Figure 15-12: Genexine - Clinical Pipeline
Figure 15-13: Levolta Pharmaceuticals – Clinical Pipeline
Figure 15-14: Neumedicines - Clinical Pipeline
Figure 15-15: Novartis - Clinical Pipeline
Figure 15-16: Oncobiologics - Clinical Pipeline
Figure 15-17: Philogen – Clinical Pipeline
Figure 15-18: Samsung Bioepis - Clinical Pipeline
Figure 15-19: Simcere Pharmaceutical Group – Clinical Pipeline
Figure 15-20: SynCore Biotechnology – Clinical Pipeline

Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development
Table 2-1: List of FDA Approved Drugs & Their Target Cancer
Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors





※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年10月24日現在 208,454 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。